Results 11 to 20 of about 4,657 (257)

Identification of PDE10A related proteins via proteomic analysis [PDF]

Annals of Medical Research, 2022
Aim: Phosphodiesterase 10A (PDE10A) regulates the expression of secondary messengers of cyclic adenosine monophosphate and cyclic guanosine monophosphate, which control several intracellular signaling pathways. Recently, deactivation of PDE10A has been a
Beker, Mustafa Çağlar, Kılıç, Ertuğrul, Yelkenci, Hayriye Ecem, Çağlayan, Berrak   +3 more
core   +3 more sources

Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy

Biomolecules, 2022
Parkinson’s disease is the second most common neurodegenerative pathology. Due to the limitations of existing therapeutic approaches, novel anti-parkinsonian medicines with non-dopamine mechanisms of action are clearly needed.
Ilya Sukhanov, Artem Dorotenko, Zoia Fesenko, Artem Savchenko, Evgeniya V. Efimova, Mikael S. Mor, Irina V. Belozertseva, Tatyana D. Sotnikova, Raul R. Gainetdinov   +8 more
doaj   +2 more sources

Alterations of striatal phosphodiesterase 10 A and their association with recurrence rate in bipolar I disorder [PDF]

Translational Psychiatry
Phosphodiesterase 10 A (PDE10A), a pivotal element of the second messenger signaling downstream of the dopamine receptor stimulation, is conceived to be crucially involved in the mood instability of bipolar I disorder (BD-I) as a primary causal factor or
Yasunori Sano, Yasuharu Yamamoto, Manabu Kubota, Sho Moriguchi, Kiwamu Matsuoka, Shin Kurose, Kenji Tagai, Hironobu Endo, Bun Yamagata, Hisaomi Suzuki, Ryosuke Tarumi, Kie Nomoto, Yuhei Takado, Kazunori Kawamura, Ming-Rong Zhang, Hajime Tabuchi, Masaru Mimura, Hiroyuki Uchida, Makoto Higuchi, Keisuke Takahata   +19 more
doaj   +2 more sources

Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil [PDF]

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
The symptoms of Alzheimer’s disease (AD) do not include only memory loss and cognitive decline but also neuropsychiatric manifestation. These AD-related symptoms are usually treated with the aid of antipsychotics; however, their effects on cognition and ...
Joanna Sikora, Maria Podsiedlik, Tadeusz Pietras, Marcin Kosmalski, Mikołaj Matłoka, Rafał Moszczyński-Petkowski, Maciej Wieczorek, Magdalena Markowicz-Piasecka   +7 more
doaj   +2 more sources

Structure‐based identification of dual ligands at the A2AR and PDE10A with anti‐proliferative effects in lung cancer cell‐lines

Journal of Cheminformatics, 2021
Enhanced/prolonged cAMP signalling has been suggested as a suppressor of cancer proliferation. Interestingly, two key modulators that elevate cAMP, the A2A receptor (A2AR) and phosphodiesterase 10A (PDE10A), are differentially co-expressed in various ...
Leen Kalash, Ian Winfield, Dewi Safitri, Marcel Bermudez, Sabrina Carvalho, Robert Glen, Graham Ladds, Andreas Bender   +7 more
doaj   +2 more sources

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects

Frontiers in Pharmacology, 2022
Background: Phosphodiesterase 10A (PDE10A) is expressed almost exclusively in the striatum and its inhibition is suggested to offer potential treatment in disorders associated with basal ganglia.
Mikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik, Maciej Wieczorek, Jerzy Pieczykolan   +18 more
doaj   +2 more sources

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. [PDF]

PLoS ONE, 2010
BackgroundHuntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from ...
Carmela Giampà, Daunia Laurenti, Serenella Anzilotti, Giorgio Bernardi, Frank S Menniti, Francesca Romana Fusco   +5 more
doaj   +3 more sources

Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects [PDF]

Molecules, 2017
Phosphodiesterase (PDE) enzymes regulate the levels of cyclic nucleotides, cAMP, and/or cGMP, being attractive therapeutic targets. In order to modulate PDE activity in a selective way, we focused our efforts on the search of allosteric modulators. Based
Ana M. García, José Brea, Alejandro González-García, Concepción Pérez, María Isabel Cadavid, María Isabel Loza, Ana Martinez, Carmen Gil   +7 more
doaj   +2 more sources

An Erythropoietin-Independent Mechanism of Erythrocytic Precursor Proliferation Underlies Hypoxia Tolerance in Sea Nomads [PDF]

Frontiers in Physiology, 2022
The Bajau Sea Nomads were recently demonstrated to have evolved larger spleens as an adaptation to millennia of a marine foraging lifestyle. The large-spleen phenotype appears to derive from increases in thyroid hormone (TH) production as a result of ...
Melissa Ilardo, Melissa Ilardo, Maria C. Ferreira dos Santos, Niels Grote Beverborg, Malini Rajan, M. Abdullah Said, Niek Verweij, Pim Van Der Harst, Peter Van Der Meer, Elizabeth A. Leibold   +9 more
doaj   +3 more sources

Second Report of PDE10A-BRAF Fusion in Pediatric Spindle Cell Sarcoma With Infantile Fibrosarcoma-Like Morphology Suggesting PDE10A-BRAF Fusion Is a Recurrent Event

Pediatric and Developmental Pathology, 2021
Infantile/congenital fibrosarcoma (IFS) is the most common soft tissue tumor in children less than one year of age. The most common anatomic site of IFS is in the extremities or trunk, and rarely in the abdomen or retroperitoneum. Approximately 70-90% of
Caitlin Hughes, Hernán Correa, Daniel J. Benedetti, Brianna N. Smith, János Sümegi, Julia A. Bridge   +5 more
openalex   +3 more sources